NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Pan Cancer T

Pan Cancer T

Private
RotterdamHealthcare & Life Scienceshttps://pancancer-t.com/

Last Round

Debt

Dec 8, 2025

Total Funding Raised

$12.84M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Pan Cancer T is a biotechnology company that develops T cell receptor (TCR) T cell therapies for solid tumors.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

T-cell receptor therapyTCR-Tsolid tumor therapycell therapyautologous cell therapycancer immunotherapytumor microenvironmentgenetic modificationdrug discovery platformnext-gen immunotherapycontract development and manufacturing organizationCDMObiotech startup

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Pan Cancer T Comps

Public and private peers based on sector, stage, and business model.

Pan Cancer T comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Pan Cancer T Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
DebtDec 8, 2025
SeedJul 11, 2024
SeedOct 28, 2021
GrantFeb 8, 2021
View all Funding Rounds

Key People

Founding team and executive leadership

Rachel Abbott

Chief Executive Officer

Executive Team

Pan Cancer T Investors

Notable investors and investment history

Pan Cancer T investors
InvestorRounds
Swanbridge CapitalSeed, Grant
Thuja CapitalSeed, Debt
Van Herk VenturesSeed, Grant, Debt
InnovationQuarterDebt, Seed
Health~HollandGrant
Erasmus MC O&O Holding B.V.Seed, Debt
View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 15, 2026

    Monthly visitors grew 282% MoM, reaching 447.

View all signals

Pan Cancer T Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Pan Cancer T Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Pan Cancer T's valuation, stock price, and market status.

Firmographic Details

HeadquartersRotterdam
Employee Range15
Year Founded2020
Last FundingDec 8, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.